Inulin and FOS
Also called: inulin-type fructans, fructooligosaccharides, oligofructose, short-chain fructooligosaccharides (scFOS), chicory inulin, beta-fructans
Inulin and fructooligosaccharides (FOS, also called oligofructose) are inulin-type fructans, a group of non-digestible carbohydrates. Health Canada lists chicory root and Jerusalem artichoke tuber as sources of both, and agave (Agave tequilana) stem and base leaves as a source of inulin.
- Category
- Other
- Forms
- Inulin (degree of polymerization, DP, 2–60), FOS/oligofructose (DP 2–10) and short-chain FOS (DP 2–5), as defined in Health Canada's Prebiotics monograph
- Strongest evidence
- A Strong
- Reviewed
- 2026-10-30
Class 1 Well studied in people. A 2024 meta-analysis pooled 55 RCTs (2,518 participants) giving adults inulin-type fructans or placebo/control for at least 2 weeks. [2]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
AStomach and gut3 topics
BBlood sugar and weight2 topics
BHeart and blood vessels1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| LDL cholesterol and triglycerides in adults | B | A 2024 meta-analysis found inulin-type fructans lowered LDL cholesterol by 0.14 mmol/L (38 RCTs, 1,879 participants; very low certainty) and triglycerides by 0.06 mmol/L (40 RCTs; low certainty); other risk factors changed little. [2] |
| Body weight in adults | B | The 2024 Talukdar meta-analysis found body weight fell 0.97 kg (36 RCTs, 1,672 participants; low certainty); effects were larger in trials of 6 weeks or more and in pre-obese and obese participants. [2] |
| BMI, fat mass and waist circumference | B | A 2024 meta-analysis of 32 studies of chicory inulin-type fructans versus placebo found lower BMI (−0.39 kg/m2), fat mass (−0.37 kg) and waist circumference (−1.03 cm). Two of three authors work for a fructan producer. [3] |
| Bowel movement frequency | B | A 2019 meta-analysis of 47 publications found short-chain β-fructans (DP below 10) increased stool frequency by 0.36 bowel movements per day; long-chain β-fructans (DP 10 or more) had no significant effect. [1] |
| Symptoms of irritable bowel syndrome (IBS) | C | A 2019 meta-analysis of 11 RCTs (729 adults with IBS or other functional bowel disorders) found prebiotics did not improve symptoms or quality of life; inulin-type fructans worsened flatulence. No included study was at low risk of bias in every category. [4] |
| Gut Bifidobacterium abundance | A | A 2023 meta-analysis (50 studies, 2,525 participants aged 0–83 years) found chicory-derived inulin-type fructans at 3–20 g/day increased Bifidobacterium abundance (SMD 0.83). Two authors are affiliated with an ingredient company. [5] |
Main constituents: Inulin-type fructans (β-fructans): short-chain forms (DP below 10, such as oligofructose) and long-chain forms (DP 10 or more) [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Studied in trials: chicory-derived inulin-type fructans at 3–20 g/day, for at least 7 days (bifidobacteria meta-analysis). [5]
- Studied in a tolerance trial: single 5 g and 10 g doses of native inulin and of oligofructose in 26 healthy adults. [6]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicines1 listed
Other medications or health products
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications1 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
Canada (Health Canada Prebiotics monograph, April 24, 2026), adults 18 years and older: prebiotic uses, inulin 5–15 g/day and FOS and/or short-chain …
Details and sources
- In a randomized, double-blind crossover trial in 26 healthy adults, both inulin fibers tended to increase gastrointestinal symptoms mildly (most often flatulence, then bloating); 10 g of oligofructose substantially increased symptoms versus control. Up to 10 g/day native inulin and 5 g/day oligofructose were well tolerated. [6]
- Health Canada requires products giving 5 g or more per day of inulin or FOS to warn of possible temporary gas and bloating, and products with inulin or FOS to say to stop use if hypersensitivity/allergy occurs. [7]
- Health Canada: inulin products for constipation must state not to use them with fever or any undiagnosed gastrointestinal trouble. [7]
Interactions
| With | What happens |
|---|---|
| Other medications or health products | Health Canada's Prebiotics monograph directs taking these products a few hours before or after other medications or health products, with at least 250 mL of liquid. [7] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- Health Canada accepts inulin with DP 2–60, FOS/oligofructose with DP 2–10 and short-chain FOS with DP 2–5; the labeled amount must reflect only the declared fructan content (dry basis). [7]
- Health Canada: validated methods such as HPLC, LC-MS and size exclusion chromatography can be used; enzymatic-gravimetric methods are not generally suitable on their own for low-molecular-weight oligosaccharides. [7]
Regulatory status
- US: FDA lists "inulin and inulin-type fructans" among non-digestible carbohydrates it intends to propose adding to the dietary fiber definition; until rulemaking is complete, FDA intends to exercise enforcement discretion to allow them in the dietary fiber declaration. [8]
- US: FDA had no questions about GRAS Notice 118 for inulin as a bulking agent in food in general (closed May 5, 2003) or GRAS Notice 44 for fructooligosaccharide in foods (closed November 22, 2000). These concern food uses. [9]
- Canada: inulin, FOS and short-chain FOS are covered by Health Canada's Prebiotics monograph (April 24, 2026) for prebiotic, fiber and constipation/regularity uses in adults. [7]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Inulin-type fructans (β-fructans): short-chain forms (DP below 10; oligomeric fructans of DP 3–9 are usually called oligofructose or FOS) and long-chain forms (DP 10 or more) Polysaccharides (fructans; oligosaccharides for short-chain forms) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming inulin as the ingredient was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29); one entry (NDI 1303) names an inulinase enzyme preparation, not inulin. FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
- FDA's published NDI notification list has 1 entry naming fructooligosaccharide (FOS), together with a Lactobacillus plantarum strain (NDI 198 submitted 2003-02-04). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P2]
- GRAS: FDA's GRAS Notice Inventory lists 6 notices with 'inulin' in the substance name (FDA had no questions for 4; FDA ceased to evaluate 2 at the notifier's request) and 12 for fructooligosaccharides or oligofructose (FDA had no questions for all 12); GRN 576 covers both. The earliest, GRN 44 (fructooligosaccharide), closed November 22, 2000. GRAS notices concern food uses. [P3]
- Dietary fiber: FDA lists inulin and inulin-type fructans among non-digestible carbohydrates it intends to propose as dietary fiber and intends to exercise enforcement discretion for their declaration meanwhile. [P4]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of inulin or fructooligosaccharides was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P5]
- The NTP Technical Reports index (TR-001 to TR-606) lists no 2-year study of inulin or fructooligosaccharides (checked 2026-10-29). [P6]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Other medications or health products: Health Canada's Prebiotics monograph: take a few hours before or after taking other medications or health products. [P7]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P8]
- Fructan content and chain length (DP) by a validated method, e.g. HPLC, LC-MS or size exclusion chromatography — Health Canada accepts only inulin DP 2–60, FOS DP 2–10 and short-chain FOS DP 2–5, labeled as declared fructan content (dry basis), and says enzymatic-gravimetric methods are not generally suitable on their own for low-molecular-weight oligosaccharides. [P7]
Supply and conservation
- Health Canada lists Cichorium intybus (chicory) root and Helianthus tuberosus (Jerusalem artichoke) tuber as sources of inulin and FOS, and Agave tequilana stem and base leaves as a source of inulin. [P7]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- Canada (Health Canada Prebiotics monograph, April 24, 2026), adults 18 years and older: prebiotic uses, inulin 5–15 g/day and FOS and/or short-chain FOS 2.5–15 g/day; source-of-fiber uses, 2–15 g/day of each; gentle constipation relief, inulin from chicory or Jerusalem artichoke 10–15 g/day, inulin from agave 7.5–15 g/day, FOS 10–15 g/day. Combined prebiotic ingredients must not exceed 15 g/day. [P7]
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- de Vries J, et al. Effects of β-fructans fiber on bowel function: a systematic review and meta-analysis. Nutrients 2019;11(1):91 (PMID 30621208), 2019-01. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. GRAS Notice Inventory (downloaded export; inventory last updated 10/21/2026; downloaded 10/29/2026), 2026-10-21. hfpappexternal.fda.gov
- FDA. Questions and Answers on Dietary Fiber (content current as of 07/25/2024), 2024-07-25. fda.gov
- IARC Monographs. List of Classifications, Volumes 1–142 (list data dated 2026-07-23; checked 2026-10-29), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program (NIEHS). Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- Health Canada NNHPD. Natural health product monograph: Prebiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/28/2026), 2026-10-28. ecfr.gov
Sources
- de Vries J, et al. Effects of β-fructans fiber on bowel function: a systematic review and meta-analysis. Nutrients 2019;11(1):91 (PMID 30621208), 2019-01. pubmed.ncbi.nlm.nih.gov
- Talukdar JR, et al. The effects of inulin-type fructans on cardiovascular disease risk factors: systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2024;119(2):496-510 (PMID 38309832), 2024-02. pubmed.ncbi.nlm.nih.gov
- Reimer RA, Theis S, Zanzer YC. The effects of chicory inulin-type fructans supplementation on weight management outcomes: systematic review, meta-analysis, and meta-regression of randomized controlled trials. Am J Clin Nutr 2024;120(5):1245-1258 (PMID 39313030), 2024-11. pubmed.ncbi.nlm.nih.gov
- Wilson B, et al. Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2019;109(4):1098-1111 (PMID 30949662), 2019-04. pubmed.ncbi.nlm.nih.gov
- Nagy DU, et al. Effect of chicory-derived inulin-type fructans on abundance of Bifidobacterium and on bowel function: a systematic review with meta-analyses. Crit Rev Food Sci Nutr 2023;63(33):12018-12035 (PMID 35833477), 2023-11. pubmed.ncbi.nlm.nih.gov
- Bonnema AL, et al. Gastrointestinal tolerance of chicory inulin products. J Am Diet Assoc 2010;110(6):865-8 (PMID 20497775), 2010-06. pubmed.ncbi.nlm.nih.gov
- Health Canada NNHPD. Natural health product monograph: Prebiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
- FDA. Questions and Answers on Dietary Fiber (content current as of 07/25/2024), 2024-07-25. fda.gov
- FDA. GRAS Notice Inventory (downloaded export; inventory last updated 10/21/2026; downloaded 10/29/2026), 2026-10-21. hfpappexternal.fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.